Market positioning Deep Bio Inc. operates in AI-driven cancer pathology with IVD SaMDs, presenting a strong opportunity to expand collaborations with hospitals, labs, and CROs seeking validated AI tools to augment pathologist workflows and biomarker quantification.

Strategic partnerships Recent and ongoing collaborations with PathAI, Roche Navify Open Environment, CancerX, and AACR-related research events indicate openness to ecosystem partnerships and platform integrations, suggesting sales motions around co-developed solutions and integrated workflows.

Regulatory readiness ISO 13485 certification and a demonstrated focus on medical device software position Deep Bio to target regulated healthcare customers with compliance-aligned deployments, enabling smoother procurement and faster deployment cycles in hospitals and diagnostic labs.

Prostate diagnostics Launch of DeepDx Prostate and focus on prostate cancer diagnostics present a clear cross-sell opportunity to expand into urology and oncology clinics, leveraging existing validated AI models to address high-demand diagnostic needs.

Market credibility Award recognition (CES Innovation Award) and status as a top AI startup in Korea, combined with revenue in the mid-range, support a value-based selling approach to large health systems and regional distributors seeking proven AI-enabled pathology solutions.